{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:37:06Z","timestamp":1771605426939,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"9961","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thelancet.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/s0140-6736(14)60920-x","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T23:19:22Z","timestamp":1409613562000},"page":"2213-2227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"title":["Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study"],"prefix":"10.1016","volume":"384","clinical-trial-number":[{"clinical-trial-number":"nct00122681","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00294047","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"S Rachel","family":"Skinner","sequence":"first","affiliation":[]},{"given":"Anne","family":"Szarewski","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Romanowski","sequence":"additional","affiliation":[]},{"given":"Suzanne M","family":"Garland","sequence":"additional","affiliation":[]},{"given":"Eduardo","family":"Lazcano-Ponce","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Salmer\u00f3n","sequence":"additional","affiliation":[]},{"given":"M Rowena","family":"Del Rosario-Raymundo","sequence":"additional","affiliation":[]},{"given":"Ren\u00e9 H M","family":"Verheijen","sequence":"additional","affiliation":[]},{"given":"Swee Chong","family":"Quek","sequence":"additional","affiliation":[]},{"given":"Daniel P","family":"da Silva","sequence":"additional","affiliation":[]},{"given":"Henry","family":"Kitchener","sequence":"additional","affiliation":[]},{"given":"Kah Leng","family":"Fong","sequence":"additional","affiliation":[]},{"given":"C\u00e9line","family":"Bouchard","sequence":"additional","affiliation":[]},{"given":"Deborah M","family":"Money","sequence":"additional","affiliation":[]},{"given":"Arunachalam","family":"Ilancheran","sequence":"additional","affiliation":[]},{"given":"Margaret E","family":"Cruickshank","sequence":"additional","affiliation":[]},{"given":"Myron J","family":"Levin","sequence":"additional","affiliation":[]},{"given":"Archana","family":"Chatterjee","sequence":"additional","affiliation":[]},{"given":"Jack T","family":"Stapleton","sequence":"additional","affiliation":[]},{"given":"Mark","family":"Martens","sequence":"additional","affiliation":[]},{"given":"Wim","family":"Quint","sequence":"additional","affiliation":[]},{"given":"Marie-Pierre","family":"David","sequence":"additional","affiliation":[]},{"given":"Doroth\u00e9e","family":"Meric","sequence":"additional","affiliation":[]},{"given":"Karin","family":"Hardt","sequence":"additional","affiliation":[]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[]},{"given":"Brecht","family":"Geeraerts","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[]},{"given":"Gary","family":"Dubin","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(14)60920-X_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey","volume":"11","author":"de Sanjos\u00e9","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(14)60920-X_bib4","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1086\/425907","article-title":"Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results","volume":"190","author":"Mu\u00f1oz","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(14)60920-X_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1055-9965.EPI-09-1235","article-title":"Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women","volume":"19","author":"Insinga","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/S0140-6736(14)60920-X_bib6","first-page":"343","article-title":"Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students","volume":"11","author":"Xi","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/S0140-6736(14)60920-X_bib7","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1086\/657083","article-title":"Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections","volume":"202","author":"Xi","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(14)60920-X_bib8","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1158\/0008-5472.CAN-10-0621","article-title":"Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity","volume":"70","author":"Trottier","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(14)60920-X_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib11","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60920-X_bib13","first-page":"1916","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60920-X_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(14)60920-X_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5694\/j.1326-5377.2008.tb01593.x","article-title":"Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?","volume":"188","author":"Skinner","year":"2008","journal-title":"Med J Aust"},{"key":"10.1016\/S0140-6736(14)60920-X_bib16","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.vaccine.2009.01.035","article-title":"Literature review of human papillomavirus vaccine acceptability among women over 26 years","volume":"27","author":"Black","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(14)60920-X_bib17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(14)60920-X_bib19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib20","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib21","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1128\/JCM.00539-06","article-title":"Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR","volume":"44","author":"van Doorn","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1128\/JCM.02831-12","article-title":"A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay","volume":"51","author":"van Alewijk","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Hum Vaccine"},{"key":"10.1016\/S0140-6736(14)60920-X_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib25","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(14)60920-X_bib26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(14)60920-X_bib27","first-page":"17","article-title":"Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16\/18) prophylactic HPV vaccines","volume":"32","author":"Syrj\u00e4nen","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/S0140-6736(14)60920-X_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(14)60920-X_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/S0140-6736(14)60920-X_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(14)60920-X_bib31","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/S0140-6736(14)60920-X_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/S0140-6736(14)60920-X_bib33","series-title":"Global Advisory Committee on Vaccine Safety. Causality assessment of adverse events following immunization","year":"2001"},{"key":"10.1016\/S0140-6736(14)60920-X_bib34","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(14)60920-X_bib35","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/cncr.10927","article-title":"Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women","volume":"95","author":"Castle","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/S0140-6736(14)60920-X_bib36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland","volume":"96","author":"French","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/S0140-6736(14)60920-X_bib37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(14)60920-X_bib38","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.vaccine.2011.01.032","article-title":"Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States","volume":"29","author":"Grant","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(14)60920-X_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","author":"Viscidi","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/S0140-6736(14)60920-X_bib40","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0140-6736(14)60920-X_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067361460920X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067361460920X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T23:41:18Z","timestamp":1598226078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067361460920X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":41,"journal-issue":{"issue":"9961","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S014067361460920X"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(14)60920-x","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(14)60920-X","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(14)61230-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}